Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale of Ra Pharmaceuticals; Is $48 a Fair Price?

SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) ("Ra Pharma") breached their fiduciary duties in connection with the proposed sale of the Company to UCB S.A.

On October 10, 2019, Ra Pharma announced that it had signed a definitive merger agreement with UCB. Under the terms of the merger agreement, Ra Pharma shareholders will receive $48.00 in cash for each share of Ra Pharma common stock they own.

The investigation concerns whether the Ra Pharma board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Ra Pharma shares of common stock.

If you are a shareholder of Ra Pharma and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP

Jim Baker, 619-814-4471

jimb@johnsonfistel.com

[Click here to join this action]

SOURCE Johnson Fistel, LLP